Abstract
In this prospective study of enteric fever, 22 patients received 400 mg of pefloxacin twice daily for 5 days (group A) and 24 received 400 mg of pefloxacin twice daily for 7 days (group B). Causative microorganisms were Salmonella typhi (8 in group A, 11 in group B) and Salmonella paratyphi B (14 in group A, 13 in group B). The clinical cure and bacterial eradication rates were 96% (21 of 22) in group A and 100% in group B. In conclusion, 5-day oral administration of pefloxacin was as effective as 7-day treatment of enteric fever caused by Salmonella spp.
Full Text
The Full Text of this article is available as a PDF (153.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ait-Khaled A., Zidane L., Amrane A., Aklil R. The efficacy and safety of pefloxacin in the treatment of typhoid fever in Algeria. J Antimicrob Chemother. 1990 Oct;26 (Suppl B):181–186. doi: 10.1093/jac/26.suppl_b.181. [DOI] [PubMed] [Google Scholar]
- Bryan J. P., Rocha H., Scheld W. M. Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones. Rev Infect Dis. 1986 Mar-Apr;8(2):189–207. doi: 10.1093/clinids/8.2.189. [DOI] [PubMed] [Google Scholar]
- Gilman R. H. General considerations in the management of typhoid fever and dysentery. Scand J Gastroenterol Suppl. 1989;169:11–18. doi: 10.3109/00365528909091326. [DOI] [PubMed] [Google Scholar]
- Hajji M., el Mdaghri N., Benbachir M., el Filali K. M., Himmich H. Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):361–363. doi: 10.1007/BF01962337. [DOI] [PubMed] [Google Scholar]
- Limson B. M., Littaua R. T. Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever. Infection. 1989 Mar-Apr;17(2):105–106. doi: 10.1007/BF01646892. [DOI] [PubMed] [Google Scholar]
- Lo W. L. Ofloxacin in treatment of typhoid fever: a preliminary study. J Antimicrob Chemother. 1988 May;21(5):681–682. doi: 10.1093/jac/21.5.681. [DOI] [PubMed] [Google Scholar]
- Peyramond D., Tigaud S., Lucht F., Vedrinne J. M., Salord F., Bertrand J. L. Bilan d'utilisation de l'ofloxacine dans le traitement d'infections variées. Pathol Biol (Paris) 1986 May;34(5):471–475. [PubMed] [Google Scholar]
- Smith M. D., Duong N. M., Hoa N. T., Wain J., Ha H. D., Diep T. S., Day N. P., Hien T. T., White N. J. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother. 1994 Aug;38(8):1716–1720. doi: 10.1128/aac.38.8.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vinh H., Wain J., Vo T. N., Cao N. N., Mai T. C., Bethell D., Nguyen T. T., Tu S. D., Nguyen M. D., White N. J. Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother. 1996 Apr;40(4):958–961. doi: 10.1128/aac.40.4.958. [DOI] [PMC free article] [PubMed] [Google Scholar]